Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which ...

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and raises full-year guidance, while navigating challenges ...

Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

The 50-day simple moving average, which is one of three major moving averages, is widely used by traders and analysts to establish support and resistance levels for a range of securities. Because it's ...

Vertex (VRTX) delivered earnings and revenue surprises of 6.05% and 3.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

FMCCH Federal Home Loan Mortgage Corporation 12.57 +5.84 (+86.78%) FMCKL Federal Home Loan Mortgage Corporation 6.82 +3.11 (+83.16%) FMCCM Federal Home Loan Mortgage Corporation 12.81 +5.81 (+83. ...

From a technical perspective, Vertex Pharmaceuticals (VRTX) is looking like an interesting pick, as it just reached a key level of support. VRTX recently overtook the 50-day moving average ...